Armodafinil Stats & Data

Reasoning for key harm-reduction additions before JSON changes:

• Longer action vs racemic modafinil and delayed peak: Armodafinil is the R-enantiomer with a mean terminal half-life ≈15 h and Tmax ~2 h (fasted). This increases late-day exposure and insomnia risk; dosing early and avoiding evening redoses reduces sleep disruption. Evidence: DrugBank monograph and clinical PK work.

• Contraception warning and timing: Modafinil-class drugs induce CYP3A and reduce steroidal contraceptive efficacy; label-derived guidance specifies backup/non-hormonal contraception during use and for 1 month after stopping. Erowid’s label excerpt states exactly “for one month after discontinuation”; armodafinil has the same mechanism (CYP3A induction), so the same precaution is applied. Clinical DDI work confirms CYP3A induction with midazolam.

• Enzyme interaction profile: Human studies show armodafinil moderately induces CYP3A4 (↓ midazolam AUC ~32% PO; ~17% IV) and inhibits CYP2C19 (↑ omeprazole AUC ~38%); it does not induce CYP1A2 (no caffeine PK change). This underpins dose/monitoring advice for CYP3A/CYP2C19 substrates.

• Antipsychotic interaction: Pretreatment with armodafinil 250 mg/day reduced aripiprazole exposure (AUC ↓ ~34%); efficacy of some antipsychotics may drop. Monitor and adjust as needed.

• Pregnancy and serious idiosyncratic reactions: Serious rashes (SJS/TEN, DRESS), psychiatric reactions (mania, psychosis), and CV events are rare but documented for modafinil/armodafinil; avoid in pregnancy and stop immediately if rash or severe psych symptoms occur. LiverTox and StatPearls summarise these risks.

• Persistent sleepiness and driving: Even with armodafinil, patients can remain sleepy; clinicians advise monitoring alertness and avoiding driving or hazardous work if impaired.

• Caffeine and stimulants: Although armodafinil does not induce CYP1A2 (no caffeine PK change), combined stimulatory effects can increase anxiety, tachycardia, and insomnia—hence conservative caffeine intake is prudent.

• Dose adjustments in hepatic impairment, older adults: Lower or half-doses recommended in severe hepatic impairment; older adults may need lower doses. (These cautions are standard across modafinil-class references.)

• Seizure risk context: Controlled data are limited; animal data are mixed and human case reports/anecdotes exist. As a HR measure with uncertain but plausible risk, combine cautiously with seizure‑threshold–lowering agents (e.g., tramadol, bupropion), prioritising sleep hygiene since sleep loss itself lowers seizure threshold. Evidence base: animal study suggesting complex pro/anticonvulsant profiles; community reports; clinician caution.

• Tolerance: Clinical texts note low abuse potential, but users report some tolerance with daily use; cycling days off can help. Data are mostly anecdotal; mark data quality accordingly.

• SWD timing and typical adult dosing: Armodafinil 150–250 mg once daily (morning; or ~1 h before shift in SWD) is standard in sleep medicine references; this anchors the “common” range and early-day dosing advice.

Harm-reduction additions integrated into JSON above reflect these points: earlier dosing, contraception backup for 1 month after, explicit CYP3A/CYP2C19 interaction guidance, psychiatric/CV monitoring, hepatic/geriatric dose reduction, conservative combination strategy with other stimulants/caffeine, and clearly annotated data quality for tolerance.

• Additional HR details:

– Hydration and periodic BP/HR checks can reduce common adverse effects like headache and palpitations; insomnia management via early dosing and sleep hygiene. Serious rash, chest pain, or psychosis warrant immediate discontinuation and medical evaluation.

– Not a substitute for adequate sleep; plan rest after prolonged wakefulness.